about
Architecture and secondary structure of an entire HIV-1 RNA genomeSelection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsProcessing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.Compensatory Evolution in RNA Secondary Structures Increases Substitution Rate Variation among SitesBottlenecks in HIV-1 transmission: insights from the study of founder virusesCompartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementiaCross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyHIV pathogenesis: dynamics and genetics of viral populations and infected cells.Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral proteaseA rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelHIV-1 Populations in Semen Arise through Multiple Mechanisms.Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophagesCompartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementiaEffect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.Evolving character of chronic central nervous system HIV infection.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsHIV-1 replication in the central nervous system occurs in two distinct cell types.Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionNelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precurDevelopment of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs.Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young childrenImpact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.Comparison of SIV and HIV-1 genomic RNA structures reveals impact of sequence evolution on conserved and non-conserved structural motifs.Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivityAlphavirus replicon particles as candidate HIV vaccines.A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsidViral protease inhibitors.Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.Accuracy of the TRUGENE HIV-1 genotyping kit.HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study.Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infectionPre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells.The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.HIV-1 target cells in the CNS.Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.HIV-1 replication capacity: Setting the pace of disease.
P50
Q24498349-A3F70109-07E1-4EEA-9C55-DE59BB4D9553Q24554340-5138EB47-C8AF-41A1-9359-E0C842AD068EQ24812175-BAFD062E-63CD-4EEF-9F50-3EC753DF1269Q27489419-2AF7A984-9216-4AA5-B245-18002B96223DQ28082862-8D3DA562-CCCE-4C0D-A422-0309621C5C4AQ28475360-A8EEE303-8CDC-494A-9842-799F9A2B5020Q28740329-82756ECA-FC86-4BBC-A140-A7541368706EQ30425443-58E6C58B-16DC-4E55-84D8-3A77D504A124Q30850215-4E7E0C5C-C564-472E-A5CE-94BA6A39FE74Q33653774-305B7D69-D8EE-4F01-9942-88F326127A2DQ33676640-482A0DB5-A290-4F60-B4CC-AEA510BC7B39Q33680752-C12417A6-EC36-422A-B0AF-B840B2F2D227Q33724200-E42B6F40-FEDF-485E-9B52-D62487218CBDQ33843510-6FEFAE6E-41F4-4F97-AFD0-0423CA382C43Q33911855-2BA2DA37-8D0A-455A-91A4-4528CA28AA1FQ33912028-94CB6CFC-51B2-40C9-BFEB-2B504D256D99Q33995713-791A9847-DF67-4888-A7A5-7FF57B383452Q34042642-21D5BA85-A631-4AE9-9AF3-79FF917E09F2Q34050421-88A4C3BA-3272-42FF-9D4E-9C170B27ED0AQ34084316-ACF6F0B2-CEDA-4F94-8EDE-9D2DDA9E98E9Q34298877-F297F98A-D45D-4DBB-9F20-057B2FD8DA9CQ34344036-679BBE18-3D36-41EE-B5CB-785C921CB976Q34435796-0F580950-C3EA-4D5F-ADAC-4EEFF2892596Q34539781-84E955E5-1C9D-4176-96F7-3282FC0A05B8Q34593647-53BFA8D2-32B7-42D6-B639-6B50165815CFQ34671913-A143396F-8DC2-41D7-ACF3-FA016E6607C4Q34717635-A4F15EC6-8AB2-4E12-9A56-1BF63454318AQ34743830-07F545E5-861E-4C3B-ACE1-276DACC48BFDQ34771244-2EA1ACB5-2C72-4D2F-BDFA-D683043286EFQ34892265-51263496-85D4-4847-8241-61B92BBBCD60Q34950897-0C0850C5-962D-4DF7-8B67-6E5A9391A43CQ34972796-7FD40BCB-731B-4626-8035-6FB06A6C2184Q35004616-8E8273AF-175B-465F-BC83-C33D957D0C9CQ35020053-9FB767AB-4CF4-4BE2-A390-26230249A738Q35061529-0F445516-A848-4D9A-9173-615701C44153Q35076645-9057C78B-D4A6-4AB6-AF80-79E4667D27ADQ35140408-EAD7317E-9791-4F93-8F86-0D0B0F90CF69Q35196509-D2EEB817-0088-4902-B067-A710BF619D3AQ35219829-CF7FC89D-133F-491B-9B8E-4A6445440397Q35229572-AA0C5F7E-2C3C-41E7-80D4-0A6D395A0D13
P50
name
Ronald Swanstrom
@ast
Ronald Swanstrom
@en
Ronald Swanstrom
@es
Ronald Swanstrom
@nl
type
label
Ronald Swanstrom
@ast
Ronald Swanstrom
@en
Ronald Swanstrom
@es
Ronald Swanstrom
@nl
prefLabel
Ronald Swanstrom
@ast
Ronald Swanstrom
@en
Ronald Swanstrom
@es
Ronald Swanstrom
@nl